FDA advisers voted in support of full approval of Paxlovid, stating that the benefits outweigh the risks of the drug for treatment of mild to moderate COVID-19.
FDA advisers voted in support of full approval of Paxlovid, stating that the benefits outweigh the risks of the drug for treatment of mild to moderate COVID-19.
